Anebulo Pharmaceuticals, Inc. logo

Anebulo Pharmaceuticals, Inc.

0001815974

Anebulo is developing innovative therapies for substance use disorders, particularly cannabinoid intoxication. They focus on evidence-based medicine to drive clinical and behavioral change, aiming to improve the lives of patients struggling with addiction. The company prioritizes the development of Selonabant for unintentional cannabis poisoning in children.

83
Meget Pålitelig
Tillitsscore

Offisielt Register

Foretaksnavn
Anebulo Pharmaceuticals, Inc.
Organisasjonsnummer
0001815974
MVA Nummer
851170950
Firmastatus
Active
Adresse
C/O ANEBULO PHARMACEUTICALS, INC., LAKEWAY, TX 78734
Bransjekoder
2834: Pharmaceutical Preparations

Sist verifisert: 1/2/2026

AI Kvalitetsanalyse

Bransje
Biotechnology
SSL/HTTPS
Sikker
Profesjonell E-post
Ja
Kontakt E-post
info@anebulo.com

🌟 Lignende Pålitelige Bedrifter

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Meget Pålitelig

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, USA
Se profil

AGENUS INC

AGENUS INC logo
86/100 · Meget Pålitelig

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, USA
Se profil

Evaxion A/S

Evaxion A/S logo
77/100 · Pålitelig

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, USA
Se profil